Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses MRNA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MRNA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Stéphane Bancel | $1,677,739 | $0 | $6,897,455 | $6,897,425 | $4,302,360 | $0 | $157,238 | $19,932,217 |
| Chief Executive Officer | ||||||||
| Stephen Hoge | 1,260,000 | 0 | 9,196,606 | 4,598,277 | 2,983,500 | 0 | 15,750 | 18,054,133 |
| President | ||||||||
| James Mock | 852,192 | 0 | 2,452,404 | 1,226,205 | 1,311,210 | 0 | 15,750 | 5,857,761 |
| Chief Financial Officer | ||||||||
| Shannon Klinger | 852,192 | 0 | 2,145,838 | 1,072,924 | 1,311,210 | 0 | 15,750 | 5,397,914 |
| Chief Legal Officer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Stéphane Bancel | $19,932,217 | $19,876,180 | $17,068,514 | +56,037 |
| Stephen Hoge | 18,054,133 | 9,181,478 | 7,339,166 | +8,872,655 |
| James Mock | 5,857,761 | 17,212,582 | 4,317,185 | −11,354,821 |
| Shannon Klinger | 5,397,914 | 17,368,701 | 4,312,496 | −11,970,787 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Mock | Chief Financial Officer | 2026-04-02 | D | 703 | $50 | $35,171 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-04-02 | — | 1,453 | — | — | 1 insider, 1 accrual row | ||
| James Mock | Chief Financial Officer | 2026-04-02 | A | 1,453 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | A | 8,116 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 5,682 | 47 | 264,952 | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | D | 4,058 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | A | 12,174 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | D | 8,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | A | 4,058 | — | — | Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | D | 12,174 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-06 | A | 12,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 4,185 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 6,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 53,336 | 48 | 2,581,462 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 47 | 433,879 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | A | 9,263 | 19 | 177,386 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 295 | 48 | 14,045 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 328 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-27 | — | 4,249 | — | — | 3 insiders, 6 accrual rows | ||
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 328 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 695 | 47 | 32,686 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 610 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 1,197 | 47 | 56,486 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | A | 9,282 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | A | 2,165 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 1,047 | 47 | 49,408 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 4,488 | 47 | 211,789 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 9,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 2,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 50 | 173,550 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 53,336 | 51 | 2,739,870 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | A | 1,452 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-02 | — | 1,452 | — | — | 1 insider, 1 accrual row | ||
| James Mock | Chief Financial Officer | 2026-07-02 | D | 703 | 73 | 50,968 | Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 18,658 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 38,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 5,733 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 7,415 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-08 | — | 1,618 | — | — | 1 insider, 1 accrual row | ||
| Stephen Hoge | President | 2026-07-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 53,336 | 68 | 3,605,514 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Mock | Chief Financial Officer | 2026-04-02 | D | 703 | $50 | $35,171 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-04-02 | D | 1,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-04-02 | A | 1,453 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | A | 8,116 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 5,682 | 47 | 264,952 | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | D | 4,058 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | A | 12,174 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | D | 8,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | A | 4,058 | — | — | Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | D | 12,174 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-06 | A | 12,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 4,185 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 6,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 53,336 | 48 | 2,581,462 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 47 | 433,879 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | A | 9,263 | 19 | 177,386 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 295 | 48 | 14,045 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 328 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 1,437 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 328 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 328 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 328 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 773 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 610 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 695 | 47 | 32,686 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 610 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 773 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 1,197 | 47 | 56,486 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | A | 9,282 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | A | 2,165 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 1,047 | 47 | 49,408 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 4,488 | 47 | 211,789 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 9,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 2,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 50 | 173,550 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 53,336 | 51 | 2,739,870 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | A | 1,452 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | D | 1,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | D | 703 | 73 | 50,968 | Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 18,658 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 38,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 5,733 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 7,415 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 1,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 53,336 | 68 | 3,605,514 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Stephen Hoge | RSU | 2025-03-01 | — | — | 148,524 | — | $4,598,303 |
| Stephen Hoge | PSU | 2025-03-01 | 74,262 | 148,524 | 148,524 | 297,048 | 4,598,303 |
| Shannon Klinger | RSU | 2025-03-01 | — | — | 34,655 | — | 1,072,919 |
| James Mock | OPTION | 2025-03-01 | — | — | — | — | 1,226,205 |
| Stephen Hoge | OPTION | 2025-03-01 | — | — | — | — | 4,598,277 |
| James Mock | RSU | 2025-03-01 | — | — | 39,606 | — | 1,226,202 |
| Shannon Klinger | OPTION | 2025-03-01 | — | — | — | — | 1,072,924 |
| Shannon Klinger | PSU | 2025-03-01 | 17,327 | 34,655 | 34,655 | 69,310 | 1,072,919 |
| Stéphane Bancel | PSU | 2025-03-01 | 111,393 | 222,786 | 222,786 | 445,572 | 6,897,455 |
| Stéphane Bancel | OPTION | 2025-03-01 | — | — | — | — | 6,897,425 |
| James Mock | PSU | 2025-03-01 | 19,803 | 39,606 | 39,606 | 79,212 | 1,226,202 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Stephen Hoge | $4,598,303 | $4,598,303 | $4,598,277 | 33.3% |
| Shannon Klinger | 1,072,919 | 1,072,919 | 1,072,924 | 33.3% |
| James Mock | 1,226,202 | 1,226,202 | 1,226,205 | 33.3% |
| Stéphane Bancel | 0 | 6,897,455 | 6,897,425 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Mock | RSU | 5,811 | — | $171,366 |
| Shannon Klinger | Option | 944 | 149.52 | — |
| Stephen Hoge | Option | 24,691 | 96.2 | — |
| Stephen Hoge | Option | 11,631 | 138.81 | — |
| Stéphane Bancel | Option | 9,148 | 149.52 | — |
| Stéphane Bancel | Option | 357,065 | 30.96 | — |
| Stephen Hoge | RSU | 3,053 | — | 90,033 |
| Shannon Klinger | Option | 55,543 | 30.96 | — |
| Shannon Klinger | RSU | 141,571 | — | 4,174,929 |
| James Mock | RSU | 6,963 | — | 205,339 |
| Shannon Klinger | RSU | 12,377 | — | 364,998 |
| James Mock | Option | 10,969 | 125.62 | — |
| Shannon Klinger | Option | 13,296 | 96.2 | — |
| Shannon Klinger | Option | 60,216 | 96.2 | — |
| James Mock | Option | 6,263 | 138.81 | — |
| Shannon Klinger | RSU | 6,963 | — | 205,339 |
| Shannon Klinger | Option | 6,263 | 138.81 | — |
| James Mock | RSU | 5,260 | — | 155,117 |
| Shannon Klinger | RSU | 5,260 | — | 155,117 |
| Shannon Klinger | RSU | 1,644 | — | 48,482 |
| Stephen Hoge | RSU | 652 | — | 19,227 |
| Stéphane Bancel | Option | 40,260 | 138.81 | — |
| Stéphane Bancel | Option | 85,469 | 96.2 | — |
| James Mock | Option | 13,296 | 96.2 | — |
| Stephen Hoge | Option | 2,644 | 149.52 | — |
| Stéphane Bancel | RSU | 222,786 | — | 6,569,959 |
| James Mock | RSU | 141,571 | — | 4,174,929 |
| Stephen Hoge | Option | 238,043 | 30.96 | — |
| Stéphane Bancel | RSU | 79,571 | — | 2,346,549 |
| James Mock | Option | 63,478 | 30.96 | — |
| Stephen Hoge | RSU | 12,931 | — | 381,335 |
| Shannon Klinger | RSU | 233 | — | 6,871 |
| James Mock | Option | 60,216 | 96.2 | — |
| James Mock | RSU | 1,644 | — | 48,482 |
| James Mock | RSU | 12,377 | — | 364,998 |
| James Mock | RSU | 39,606 | — | 1,167,981 |
| Stephen Hoge | RSU | 148,524 | — | 4,379,973 |
| Shannon Klinger | RSU | 34,655 | — | 1,021,976 |
| Stephen Hoge | RSU | 22,987 | — | 677,887 |
| Stéphane Bancel | RSU | 22,543 | — | 664,793 |
| Stephen Hoge | RSU | 9,768 | — | 288,058 |
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance and impact.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-06 | 169,401,841 | 90,761,924 | 440,050 | 65.11% | Passed |
| 2024 | 2024-05-06 | 248,175,284 | 25,923,518 | 488,279 | 90.54% | Passed |
| 2023 | 2023-05-03 | 254,146,335 | 34,946,612 | 1,618,048 | 87.91% | Passed |
| 2022 | 2022-04-28 | 277,970,064 | 20,992,879 | 442,036 | 92.98% | Passed |
| 2021 | 2021-04-28 | 222,266,802 | 16,973,022 | 2,483,790 | 91.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-06 | 65.11%a |
| 2024 | 2024-05-06 | 90.54%b |
| 2023 | 2023-05-03 | 87.91%c |
a. Approved under the standard stated in the filing — “2, the abstention will have no effect on the results of this vote.”.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “2, the abstention will have no effect on the results of this vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 89 : 1 |
|---|---|
| CEO total compensation | $19,932,217 |
| Median employee compensation | $225,053 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Noubar Afeyan, Ph.DNot independent · Board Chair | $130,000 | — | $463,281 | $0 | $65,142 | $658,423 |
| François Nader, M.DIndependent · Compensation and Talent (Chair) · Nominating and Corporate Governance (Chair) | 120,000 | 347,446 | 115,821 | 0 | — | 583,267 |
| Sandra Horning, M.DIndependent · Product and Technology (Chair) · Nominating and Corporate Governance | 100,000 | 463,290 | — | 0 | — | 563,290 |
| Elizabeth TallettIndependent · Audit (Chair) · Compensation and Talent | 100,000 | 115,816 | 347,461 | 0 | — | 563,277 |
| Abbas HussainIndependent · Audit · Product and Technology | 80,000 | 463,290 | — | 0 | — | 543,290 |
| Elizabeth Nabel, M.DIndependent · Compensation and Talent · Product and Technology | 80,000 | 463,290 | — | 0 | — | 543,290 |
| Paul SaganIndependent · Audit · Nominating and Corporate Governance · Not standing for re-election | 80,000 | — | 463,281 | 0 | — | 543,281 |
| David RubensteinIndependent · Audit | 80,000 | 231,631 | 231,641 | 0 | — | 543,272 |
| Stéphane BancelEmployee director · Board Chair · Executive (Chair) | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $80,000 |
|---|---|
| Annual equity retainer | $425,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 6x annual cash retainer ($480,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $770,000 |
| Equity awards (grant-date value) | $2,084,763 |
| All other compensation | $65,142 |
| Total cost of the board | $2,919,905 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Moderna, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Moderna, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Biogen | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 4 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 5 | BioMarin Pharmaceutical | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Bristol-Myers Squibb | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 7 | Vertex Pharmaceuticals | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 8 | Merck | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 9 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 10 | Jazz Pharmaceuticals | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 11 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 12 | BeOne Medicines | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 13 | Alnylam Pharmaceuticals | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 14 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 15 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 16 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 17 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 18 | Regeneron Pharmaceuticals | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Alnylam Pharmaceuticals | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| BeOne Medicines | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Biogen | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Bristol-Myers Squibb | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Incyte Corporation | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Jazz Pharmaceuticals | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Merck | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Neurocrine Biosciences | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Regeneron Pharmaceuticals | 155% | Options 60 · RSA 40 | not disclosed | Pay Governance LLC |
| Sarepta Therapeutics | 100% | RSU 50 · PSU 50 | No | FW Cook |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
| Vertex Pharmaceuticals | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Stéphane Bancel | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 2 | Section 01, Stephen Hoge | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 18,054,133. Filing ↗machine: r8 · c45 · span 1153380–1153390 |
| 3 | Section 01, James Mock | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 5,857,761. Filing ↗machine: r5 · c45 · span 1143143–1143152 |
| 4 | Section 01, Shannon Klinger | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 5,397,914. Filing ↗machine: r11 · c45 · span 1164089–1164098 |
| 5 | Section 03, Stephen Hoge RSU | DEF 14A | — | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 6 | Section 03, Stephen Hoge PSU | DEF 14A | — | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Shannon Klinger RSU | DEF 14A | — | 0001308179-26-000081 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t165 · r14 · c6 · span 1426279–1426285 |
| 8 | Section 03, James Mock OPTION | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t161 · r5 · c14 · span 1208180–1208189 |
| 9 | Section 03, Stephen Hoge OPTION | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t157 · r8 · c15 · span 1152529–1152538 |
| 10 | Section 03, James Mock RSU | DEF 14A | — | 0001308179-26-000081 | Section “FASB ASC T” · grants of plan-based awards table. Filing ↗machine: t163 · r29 · c6 · span 1319943–1319949 |
| 11 | Section 03, Shannon Klinger OPTION | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t161 · r11 · c14 · span 1221767–1221776 |
| 12 | Section 03, Shannon Klinger PSU | DEF 14A | — | 0001308179-26-000081 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t165 · r14 · c6 · span 1426279–1426285 |
| 13 | Section 03, Stéphane Bancel PSU | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t163 · r15 · c6 · span 1279780–1279787 |
| 14 | Section 03, Stéphane Bancel OPTION | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t161 · r3 · c16 · span 1203288–1203297 |
| 15 | Section 03, James Mock PSU | DEF 14A | — | 0001308179-26-000081 | Section “FASB ASC T” · grants of plan-based awards table. Filing ↗machine: t163 · r29 · c6 · span 1319943–1319949 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “CEO Pay Ratio”. As printed: 89 : 1. Filing ↗machine: span 1528497–1528504 |
| 17 | Section 08, Noubar Afeyan, Ph.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 658,423. Filing ↗machine: t95 · r2 · c16 · span 617356–617363 |
| 18 | Section 08, François Nader, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 583,267. Filing ↗machine: t95 · r6 · c13 · span 627526–627533 |
| 19 | Section 08, Sandra Horning, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 563,290. Filing ↗machine: t95 · r3 · c13 · span 619900–619907 |
| 20 | Section 08, Elizabeth Tallett | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 563,277. Filing ↗machine: t95 · r9 · c13 · span 635627–635634 |
| 21 | Section 08, Abbas Hussain | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,290. Filing ↗machine: t95 · r4 · c13 · span 622435–622442 |
| 22 | Section 08, Elizabeth Nabel, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,290. Filing ↗machine: t95 · r5 · c13 · span 624978–624985 |
| 23 | Section 08, Paul Sagan | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,281. Filing ↗machine: t95 · r8 · c13 · span 632596–632603 |
| 24 | Section 08, David Rubenstein | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,272. Filing ↗machine: t95 · r7 · c13 · span 630064–630071 |
| 25 | Section 08, Stéphane Bancel | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Abbas Hussain 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, David Rubenstein 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Abbas Hussain 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Elizabeth Tallett 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Elizabeth G. Nabel 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Francois Nader 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Abbas Hussain 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, David Rubenstein 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Sandra Horning 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Elizabeth G. Nabel 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Elizabeth Tallett 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Sandra Horning 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Francois Nader 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Sandra Horning 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Noubar Afeyan 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Sandra Horning 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Francois Nader 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, David Rubenstein 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, David Rubenstein 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Francois Nader 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Elizabeth G. Nabel 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Abbas Hussain 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Elizabeth Tallett 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Soria Ester Banque 2026-07-05 | Form 4 | 2026-07-07 | 0001682852-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Soria Ester Banque 2026-07-05 | Form 4 | 2026-07-07 | 0001682852-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 06, 2026 vote | Form 8-K | 2026-05-11 | 0001682852-26-000101 | Item 5.07 · say-on-pay result. As reported: 65.11% (votes for as printed: 169,401,841). Filing ↗ |
| 115 | Section 06, 2024 vote | Form 8-K | 2024-05-09 | 0001682852-24-000031 | Item 5.07 · say-on-pay result. As reported: 90.54% (votes for as printed: 248,175,284). Filing ↗ |
| 116 | Section 06, 2023 vote | Form 8-K | 2023-05-05 | 0001193125-23-137079 | Item 5.07 · say-on-pay result. As reported: 87.91% (votes for as printed: 254,146,335). Filing ↗ |
| 117 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 118 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 119 | Section 09b board cost (computed) | Computed | — | computed | Cash 770,000 + equity 2,084,763 + all other 65,142 = 2,919,905, summed across the director compensation table rows.machine: formula: Σ = 2,919,905 |
| 120 | Exelixis, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 121 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 122 | Biogen, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen's own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 123 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 124 | BioMarin Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 125 | Bristol-Myers Squibb, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 126 | Vertex Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 127 | Merck, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck's own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 128 | Moderna, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 129 | Jazz Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 130 | United Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 131 | BeOne Medicines, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-049655 | CEO total compensation as printed in BeOne Medicines's own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021 |
| 132 | Alnylam Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals's own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 133 | Neurocrine Biosciences, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 134 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 135 | Ultragenyx Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 136 | Sarepta Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 137 | Regeneron Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 138 | Section 10a, Jazz Pharmaceuticals reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 139 | Section 10a, Sarepta Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 140 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 141 | Section 10a, Ultragenyx Pharmaceutical reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 142 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 143 | Section 10a, Bristol-Myers Squibb reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 144 | Section 10a, United Therapeutics reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 145 | Section 10a, BeOne Medicines reciprocity | DEF 14A | — | 0001104659-26-049655 | BeOne Medicines names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 146 | Section 10a, Exelixis reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 147 | Section 10a, Alnylam Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 148 | Section 10a, Merck reciprocity | DEF 14A | — | 0001193125-26-147704 | Merck's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 149 | Section 10a, BioMarin Pharmaceutical reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 150 | Section 10a, Neurocrine Biosciences reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 151 | Section 10a, Regeneron Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 152 | Section 10a, Vertex Pharmaceuticals reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |